Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Antibiotic levels measured in lungs of sickest pneumonia patients

NCT ID NCT04171674

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how the antibiotic ceftobiprole moves through the blood and lungs of 12 adults with severe pneumonia who were on breathing machines. Researchers gave a high dose continuously through a vein and took blood and lung fluid samples to measure drug levels. The goal was to find the best dose to fight the infection effectively.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ceftobiprole (a high-dose antibiotic given continuously through a vein)
What this could lead to
If successful, this could help doctors determine the right dose of ceftobiprole for critically ill pneumonia patients on ventilators.
What could go wrong
This is a very small, early-stage study (12 people) focused on drug levels, not on proving the drug works or is safe. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

12 people

The number who actually took part.

Started

Apr 2021

Finished

Jan 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All patients (or his/her representative for those patients who are unable to express their consent) who have given free, informed consent, and signed the consent form. * All patients affiliated to or benefitting from a health insurance scheme. * All patients hospitalised in the intensive care unit with severe acute community-acquired pneumonia requiring the use of mechanical ventilation: this is characterised by signs and symptoms corresponding to an infection of the lower respiratory tract and imaging data corresponding to bacterial pneumonia.The patient has been under mechanical ventilation for less than 24 hours. Exclusion Criteria: * Any patient who is already taking part in another interventional study that may influence the main criterion for judgement. * Any patient who is in the exclusion period determined by another study. * Any patient under curatorship or guardianship established by a court * Any patient who is pregnant, about to give birth or breastfeeding. * Any patient with a contra-indication or allergy to beta-lactams * Any patient whose survival is estimated at less than 48 hours * Any patient whose discharge from hospital is planned for 24 hours after admission * Any patient whose creatinine clearance is estimated at less than 50 ml/min or who is undergoing renal replacement therapy * Any patient undergoing extracorporeal life support.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pneumonia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Community-Acquired Pneumonia pneumonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pneumonia

Contacts and locations

Locations

  • CHU de Nîmes

    Nîmes, Gard, 30029, France

  • Centre Hospitalier Lyon Sud,

    Pierre-Bénite, Auvergne-Rhône-Alpes, 69310, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.